BOUTROS, ANDREA
BOUTROS, ANDREA
100007 - Dipartimento di Medicina interna e specialità mediche
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
2020-01-01 Boutros, A.; Schiavi, C.; Cecchi, F.; Spagnolo, F.; Guadagno, A.; Tanda, E. T.; Giusti, F.; Murdaca, G.; Queirolo, P.
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
2022-01-01 Boutros, Andrea; Vera, Lara; Gatto, Federico; Fornarini, Giuseppe; Zanardi, Elisa
Current State of Target Treatment in BRAF Mutated Melanoma
2020-01-01 Tanda, E. T.; Vanni, I.; Boutros, A.; Andreotti, V.; Bruno, W.; Ghiorzo, P.; Spagnolo, F.
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
2023-01-01 Boutros, Andrea; Croce, Elena; Tanda, Enrica Teresa; Cecchi, Federica; Arecco, Luca; Genova, Carlo; Baldelli, Ilaria; Lambertini, Matteo; Raposio, Edoardo; Del Mastro, Lucia; Spagnolo, Francesco
Enhanced patient journey associated with improved overall survival in colon cancer patients: A study by the Ligurian Oncology Network
2024-01-01 Boutros, Andrea; Diaz Gaitan, Nidia Sofia; Orengo, Giovanni; Blondeaux, Eva; Pastorino, Alessandro; Zacconi, Monica; Ferrè, Francesca; Boni, Luca; Cardinali, Barbara; Del Mastro, Lucia
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
2023-01-01 Queirolo, P.; Cinquini, M.; Argenziano, G.; Bassetto, F.; Bossi, P.; Boutros, A.; Clemente, C.; de Giorgi, V.; Del Vecchio, M.; Patuzzo, R.; Peris, K.; Quaglino, P.; Reali, A.; Zalaudek, I.; Spagnolo, F.
Immune Checkpoint Inhibitors-Related Myastenia Gravis, Myocarditis and Myositis: A Systematic Review of Cases
2024-01-01 Scarsi, Elena; Massucco, Sara; Hamedani, Mehrnaz; Faedo, Elena; Boutros, Andrea; Genova, Carlo; Schenone, Angelo; Grandis, Marina
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
2019-01-01 Queirolo, P.; Boutros, A.; Tanda, E.; Spagnolo, F.; Quaglino, P.
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
2021-01-01 Tanda, E. T.; D'Amato, A. L.; Rossi, G.; Croce, E.; Boutros, A.; Cecchi, F.; Spagnolo, F.; Queirolo, P.
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma
2020-01-01 Spagnolo, F.; Croce, E.; Boutros, A.; Tanda, E.; Cecchi, F.; Mascherini, M.; Solari, N.; Cafiero, F.; Queirolo, P.
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
2020-01-01 Vanni, I.; Tanda, E. T.; Dalmasso, B.; Pastorino, L.; Andreotti, V.; Bruno, W.; Boutros, A.; Spagnolo, F.; Ghiorzo, P.
Primary endobronchial melanoma: a case report and clinical management indications
2024-01-01 Barisione, Emanuela; Boutros, Andrea; Mora, Marco; Spagnolo, Francesco; Tanda, ENRICA TERESA; Genova, Carlo; Tagliabue, Elena
The adjuvant treatment revolution for high-risk melanoma patients
2019-01-01 Spagnolo, F.; Boutros, A.; Tanda, E.; Queirolo, P.
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
2023-01-01 Boutros, A.; Carosio, R.; Campanella, D.; Spagnolo, F.; Banelli, B.; Morabito, A.; Pistillo, M. P.; Croce, E.; Cecchi, F.; Pronzato, P.; Queirolo, P.; Raposio, E.; Fontana, V.; Tanda, E. T.
The treatment of advanced melanoma: Current approaches and new challenges
2024-01-01 Boutros, A.; Croce, E.; Ferrari, M.; Gili, R.; Massaro, G.; Marconcini, R.; Arecco, L.; Tanda, E. T.; Spagnolo, F.
Tisotumab vedotin
2020-01-01 D'Alessandro, G.; Barra, F.; Boutros, A.; Evangelisti, G.; Desideri, L. F.; Moioli, M.; Ferrero, S.
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
2021-01-01 Spagnolo, F.; Boutros, A.; Cecchi, F.; Croce, E.; Tanda, E. T.; Queirolo, P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient | 1-gen-2020 | Boutros, A.; Schiavi, C.; Cecchi, F.; Spagnolo, F.; Guadagno, A.; Tanda, E. T.; Giusti, F.; Murdaca, G.; Queirolo, P. | |
| Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients | 1-gen-2022 | Boutros, Andrea; Vera, Lara; Gatto, Federico; Fornarini, Giuseppe; Zanardi, Elisa | |
| Current State of Target Treatment in BRAF Mutated Melanoma | 1-gen-2020 | Tanda, E. T.; Vanni, I.; Boutros, A.; Andreotti, V.; Bruno, W.; Ghiorzo, P.; Spagnolo, F. | |
| Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma | 1-gen-2023 | Boutros, Andrea; Croce, Elena; Tanda, Enrica Teresa; Cecchi, Federica; Arecco, Luca; Genova, Carlo; Baldelli, Ilaria; Lambertini, Matteo; Raposio, Edoardo; Del Mastro, Lucia; Spagnolo, Francesco | |
| Enhanced patient journey associated with improved overall survival in colon cancer patients: A study by the Ligurian Oncology Network | 1-gen-2024 | Boutros, Andrea; Diaz Gaitan, Nidia Sofia; Orengo, Giovanni; Blondeaux, Eva; Pastorino, Alessandro; Zacconi, Monica; Ferrè, Francesca; Boni, Luca; Cardinali, Barbara; Del Mastro, Lucia | |
| Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology | 1-gen-2023 | Queirolo, P.; Cinquini, M.; Argenziano, G.; Bassetto, F.; Bossi, P.; Boutros, A.; Clemente, C.; de Giorgi, V.; Del Vecchio, M.; Patuzzo, R.; Peris, K.; Quaglino, P.; Reali, A.; Zalaudek, I.; Spagnolo, F. | |
| Immune Checkpoint Inhibitors-Related Myastenia Gravis, Myocarditis and Myositis: A Systematic Review of Cases | 1-gen-2024 | Scarsi, Elena; Massucco, Sara; Hamedani, Mehrnaz; Faedo, Elena; Boutros, Andrea; Genova, Carlo; Schenone, Angelo; Grandis, Marina | |
| Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy | 1-gen-2019 | Queirolo, P.; Boutros, A.; Tanda, E.; Spagnolo, F.; Quaglino, P. | |
| Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? | 1-gen-2021 | Tanda, E. T.; D'Amato, A. L.; Rossi, G.; Croce, E.; Boutros, A.; Cecchi, F.; Spagnolo, F.; Queirolo, P. | |
| Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma | 1-gen-2020 | Spagnolo, F.; Croce, E.; Boutros, A.; Tanda, E.; Cecchi, F.; Mascherini, M.; Solari, N.; Cafiero, F.; Queirolo, P. | |
| Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications | 1-gen-2020 | Vanni, I.; Tanda, E. T.; Dalmasso, B.; Pastorino, L.; Andreotti, V.; Bruno, W.; Boutros, A.; Spagnolo, F.; Ghiorzo, P. | |
| Primary endobronchial melanoma: a case report and clinical management indications | 1-gen-2024 | Barisione, Emanuela; Boutros, Andrea; Mora, Marco; Spagnolo, Francesco; Tanda, ENRICA TERESA; Genova, Carlo; Tagliabue, Elena | |
| The adjuvant treatment revolution for high-risk melanoma patients | 1-gen-2019 | Spagnolo, F.; Boutros, A.; Tanda, E.; Queirolo, P. | |
| The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors | 1-gen-2023 | Boutros, A.; Carosio, R.; Campanella, D.; Spagnolo, F.; Banelli, B.; Morabito, A.; Pistillo, M. P.; Croce, E.; Cecchi, F.; Pronzato, P.; Queirolo, P.; Raposio, E.; Fontana, V.; Tanda, E. T. | |
| The treatment of advanced melanoma: Current approaches and new challenges | 1-gen-2024 | Boutros, A.; Croce, E.; Ferrari, M.; Gili, R.; Massaro, G.; Marconcini, R.; Arecco, L.; Tanda, E. T.; Spagnolo, F. | |
| Tisotumab vedotin | 1-gen-2020 | D'Alessandro, G.; Barra, F.; Boutros, A.; Evangelisti, G.; Desideri, L. F.; Moioli, M.; Ferrero, S. | |
| Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review | 1-gen-2021 | Spagnolo, F.; Boutros, A.; Cecchi, F.; Croce, E.; Tanda, E. T.; Queirolo, P. |